1Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissue from cytotoxic therapies by amifostine [J]. Semin Oncol, 1999,26(suppl 7) :3.
2Betas JS, Ford PA. Renal toxicities of antineoplastic drugs and bone marrow transplantation[J]. Semin Nephrol, 1997,17( 1 ) :54-66.
2Koukourakis MI. Amifostine in clinical oncology: current use and future applications. Anticancer Drugs, 2002, 13 : 81-209.
3Brizel DM, Wasserman TH, Stmad V, et al. Final report of a phase Ⅲ randomized trial of amifostine as a radioprotectant in head and neck cancer. Int J Radiat Oncol Biol Phys, 1999, 45 (Suppl 1):147-148.
4Hensley ML, Schuchter LM, Lindley C. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectors. J Clin Oncol, 1999, 17: 3333-3355.
5Marzatico F, Porta C, Moroni M, et al. In vitro antioxidant properties of amifostine (WR-2721, Ethyol). Cancer Chemother Pharmaeol, 2000, 45: 172.
6Philips TL. Rationale for initial clinical trials and future development of radioprotectors. Cancer Clin Trials, 1980, 3: 165-173.
7Wasserman TH, Brizel DM, Michael H, et al. Influence of intravenous amifostine on xerostomla, tumor, control and survival after radiotherapy for head-and-neck cancer: 2-year follow-up of a prospective, randomized, phase Ⅲ trail. Int J Radiat Oncol Biol Phys, 2005, 63: 985-990.
8Jellema AP, Slotman BJ, Muller M, et al. Radiotherapy alone versus radiotherapy with amifostine 3 times a week versus radiotherapy with amifestine 5 times a week: a prospective randomized study in squamous cell head and neck cancer. Eur J Cancer, 2005, 3 : S294.
9Sasse AD, Clark LG, Sasse EC, et al. Amifostine reduces side effects and improves complete response rate during radiotherapy:results of a meta-analysis. Int J Radiat Oncol Biol Phys, 2006, 64:784-791.
10Meirovitz A, Ben-Jesef E, Ensminger WD, et al. Phase I whole-liver radiation dose escalation trial using amifestine as a radioproteetor. Int J Radiat Oncol Biol Phys, 2004, 60: S427.
9Gronberg BH,Bremnes RM,Flotten O,et al.Phase III study by the Norwegian lung cancer study group:pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer[J] .Clin Oncol,2009,27(19):3217-3224.
10Kouvaris JR,Kouloulias VE,Vlahos LJ.Amifostine:the first selective-target and broad-spectrum radioprotector[J] .Oncologist,2007,12(6):738-747.
